

# Vaishali Pharma Ltd.



**CORPORATE & REGISTERED OFFICE :**  
706-709, 7th Floor, Aravali Business Centre,  
R. C. Patel Road, Off. Sodawala Lane,  
Borivali (West), Mumbai-400 092.  
Tel.: +91-22-4217 1819  
E-mail : sales@vaishalipharma.com  
**CIN - L52310MH2008PLC181632**



22nd June, 2021

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1,  
G Block, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051

**Stock Code: VAISHALI**

Dear Sir/Madam,

**SUB: THE COMPANY HAS RECEIVED SUPPLY ORDERS IN EXCESS OF 100,000 US DOLLARS FROM RUSSIA.**

We are very pleased to inform our shareholders that we see greater demand of our products which is backed by marketing strategies. *The Company has received an order in excess of 100,000 US Dollars from Russia for the Supply of our registered Veterinary product. We are glad that the quality is well accepted & has meet with satisfactory response.*

Please find enclosed herewith a copy of Press Release giving information about the same and many more.

We request you to kindly take the same on record.

Thanking you.

Yours faithfully,  
**For Vaishali Pharma Limited**

**Atul Arvind Vasani**  
Managing Director



**PRESS RELEASE**

**THE COMPANY HAS RECEIVED SUPPLY ORDERS IN EXCESS OF 100,000 US DOLLARS FROM RUSSIA.**

**Mumbai, June 22, 2021:** Vaishali Pharma Limited (NSE:- VAISHALI), a Mumbai based Company, engaged in supply of pharmaceutical products to corporates, hospitals and retails stores in all SKUs required. Our products have made its grasp on the overseas market and getting an excellent feedback worldwide. The Company is showing consistent agility and innovation by meeting the needs of its customers in both Domestic and International markets.

We are pleased to inform our shareholders that we see greater demand of our products which is backed by our marketing strategies. Yet again, **the Company has received an order in excess of 100,000 US Dollars from Russia for the Supply of our registered Veterinary product.** We are glad that the quality is well accepted & has started receiving good response. Vaishali Pharma has predominantly built portfolio into Veterinary products apart from range of other products in each and every segment. The company is striving hard to double the product range in coming years and working in that direction with registration of products in various countries after receiving such good response.

**Adapting quickly to the ever-lasting demands, we have emerged as one of the fastest growing organisation in the export of Pharmaceutical products across the globe, and currently the company has undertaken to export pharmaceutical, surgical and veterinary products to various countries.**

**ABOUT VAISHALI PHARMA LIMITED:**

Vaishali Pharma Limited (NSE: VAISHALI), abided by the norms of extending uncompromised quality products, has raised the standards of the Pharmaceutical & Healthcare industry time and again. Through unwavering dedication, consistent efforts and endless innovation we enjoy an Export House status. Company's products' quality is certified by ISO 9001:2015 certification for the Quality Management from ISC Global.

In business since 1989, Vaishali Pharma Limited is a globally well trusted brand with high quality products, accepted by companies across the globe. The Company is amongst the leading players in the supply of pharma products – Bulk Drugs / APIs, Formulations, Surgical Products, Veterinary supplements, Herbal & Nutraceutical products, with a well-established brand known for its high-quality products & services amongst various clients globally. The company has over 150+ formulation brands marketed in multiple countries; of which dossier is in CTD format along with its respective bioequivalence. The company has built a robust pipeline of around 250 Dossiers. The Company's synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with clients.

Strong commitment of providing quality products is backed by in-depth industry knowledge, well-qualified team of professionals, as well as hi-tech and advanced infrastructure. Resulting in creating mutually beneficial associations for all the clients.

Adapting quickly to the ever-evolving demands, the Company has emerged as one of the fastest growing organization in the pharmaceutical industry in export of healthcare products from India. With headquarters located in the economic hub of India, Mumbai.

At Vaishali Pharma, we are working tirelessly to make available health improving pharmaceutical products affordable and accessible to all. Looking beyond this immediate term, the upcoming half year shall present more good opportunities for the Company and we shall continue to perform better than the previous half year.

Adhering to high quality standards is not an accident but our habit. Passionate to be the best, we take pride in what we do and strive to deliver products with zero defects. One can count upon us for quality pharmaceutical and healthcare products.

**For more details please visit:** [www.vaishalipharma.com](http://www.vaishalipharma.com)

**For any Investor Relations query, please contact:**

**Mr. Akshay Jharkhandi**  
**Company Secretary**

Email: [cs@vaishalipharma.com](mailto:cs@vaishalipharma.com)

**Mr. Ratnesh Singh**  
**Chief Financial Officer**

Email: [investor@vaishalipharma.com](mailto:investor@vaishalipharma.com)

**Note:** Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.